Amitai(I),Zlotnik(M),Ram(R),Amit(O),Sherba... Leuk Res 2026-08-12

...ELN-2022 adverse risk. After a single treatment course, the composite complete remission rate (CRc) was 45% and the over...

Murdock(HM),Hebert(K),Gooptu(M),Shapiro(R)... Transplant Cell Ther 2026-08-19

...ELN 2017/2022 or therapy-related AML) or adverse risk MDS (IPSS Intermediate-2/High or MDS with high-risk mutations). We...

Prin-Felix(L),Jullien(M),Peterlin(P),Le Bo... Bone Marrow Transplant 2026-08-19

...ELN-2017 risk score, was associated with lower OS and DFS. CloT3 was independently associated with improved OS (p = 0.03...

Jäger(C),Zagrodnick(M),Schwede(B),Christop... PLoS One None

...ELN. ELNs can support transparent, collaborative, and sustainable research data management when combined with structured...

Chang(G),Shi(P),Dou(L),Ren(J),Zhang(H),Jia... Br J Haematol 2026-08-21

...ELN) recommendation redefined favourable-risk CCAAT/enhancer binding protein alpha (CEBPA)-mutated acute myeloid leukaem...

Takagi(F),Ono(T),Takahashi(N),Minami(Y),Na... Blood Adv 2026-08-14

...ELN 2025-defined "Warning" category as an initial adverse state in the definition of FFS events and evaluated transition...

Espinoza-Gutarra(MR),Jarret(B),Wang(X),Afg... Cancer Rep (Hoboken) 2026-08-00

...ELN risk classification (vs. adverse; p = 0.032). When restricted to patients treated with TKI at 2L+ without prior SCT,...

Steiner(L),Silva-Bermudez(LS),Ghazal(M),Ab... Eur J Haematol 2026-07-30

...ELN 2024 risk and age ≥ 75 years were associated with inferior OS, whereas the 7d schedule remained associated with impr...

Karnik(S),Zimmer(J),Gutekunst(M),Gorityala... Bioanalysis None

...ELN/LIMS. Conclusions and consensus from discussions of these topics are included in this article.

El-Sayed(HA),Sakr(DH),Ebrahim(MA),Alghando... Clin Exp Med 2026-07-20

...ELN) risk stratification for AML. vWF-ag, vWF: RCof, FVIII, and D-dimer were measured at diagnosis and at remission. Adv...